A mixed performance in the stock price over the year has left investors with either an optimistic or pessimistic outlook, depending on their point of view. The index has shown a price gain of 12.41% this year. Over the last six months, there has been a stronger performance of -19.81%. The price of NTLA fallen by 8.25% during the last 30 days period. For the last 5-days stocks have slided -8.71%.
Intellia Therapeutics Inc. (NTLA) has a current stock price of $39.22. During the previous trading session, the stock witnessed a notable rise, reaching a high of $41.65 after opening at $41.65. The stock’s low for the day was $38.90, and it eventually closed at $41.76.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
The stock market performance of Intellia Therapeutics Inc. has been fairly unsteady. Over the last year, the company’s stock hit its highest at $76.45 on 08/03/22, while the lowest price during the same time frame was $32.44, recorded on 01/20/23.
52-week price history of NTLA Stock
A stock’s 52-week price history, including the low and high prices, can offer valuable insights into its current standing and future prospects. Intellia Therapeutics Inc.’s current trading price is -48.70% away from its 52-week high, while its distance from the 52-week low is 20.92%. The stock’s price range over this timeframe has been between $32.44 and $76.45. The shares of the Healthcare sector company recorded a trading volume of approximately 1.18 million for the day, which was comparatively higher than the average daily volume of 1.11 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
Intellia Therapeutics Inc. (NTLA) has experienced a quarterly rise of 3.92% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 3.53B and boasts a workforce of 598 employees.
Expert Opinions: Analysts’ Ratings for Intellia Therapeutics Inc.
As of right now, 22 analysts are rating Intellia Therapeutics Inc. as a BUY, 3 of the polled analysts branded the stock as an OVERWEIGHT, 4 analysts are recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
How Moving Averages and Trading Volume Data Work Together
Based on Barchart.com data, the company’s moving average over the 100-day period was 39.38, with a change in price of +4.33. Similarly, Intellia Therapeutics Inc. recorded 1,106,788 in trading volume during the last 100 days, posting a change of +12.41%.
NTLA’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for NTLA stands at 0.00. Similarly, the long-term debt-to-equity ratio is also 0.00.
NTLA Stock Stochastic Average
Intellia Therapeutics Inc.’s raw stochastic average for the past 50 days is currently at 38.27%. This represents a surge from the raw stochastic average of the last 20 days, which was recorded at 31.57%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 51.47% and 61.86%, respectively.
